This is the authors' abstract. We don't add key points for this paper.
People living in prison are disproportionately affected by hepatitis B and C, yet access to prevention, testing, and treatment services remains inconsistent across Europe. Addressing this gap is critical to achieving viral hepatitis elimination targets by 2030. EuroHePP is a European toolkit developed to support national responses to viral hepatitis in prison settings. It was created through a structured, multi-stage process involving evidence review, stakeholder consultations, and expert validation. The toolkit provides practical guidance across the full continuum of care, including prevention, testing, treatment, and monitoring, and promotes micro-elimination approaches tailored to prison populations. It emphasises evidence-based interventions such as opt-out testing, decentralised and simplified models of care, harm reduction strategies, and continuity of care after release. By offering adaptable tools and frameworks for policymakers and practitioners, EuroHePP aims to strengthen prison health systems, reduce health inequalities, and accelerate progress towards hepatitis elimination at national and regional levels.
No takes yet. Share an insight, caveat, or question.
Fondelli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: